178 related articles for article (PubMed ID: 32669430)
1. Chimeric hemagglutinin vaccine elicits broadly protective CD4 and CD8 T cell responses against multiple influenza strains and subtypes.
Liao HY; Wang SC; Ko YA; Lin KI; Ma C; Cheng TR; Wong CH
Proc Natl Acad Sci U S A; 2020 Jul; 117(30):17757-17763. PubMed ID: 32669430
[TBL] [Abstract][Full Text] [Related]
2. Induction of Broad-Based Immunity and Protective Efficacy by Self-amplifying mRNA Vaccines Encoding Influenza Virus Hemagglutinin.
Brazzoli M; Magini D; Bonci A; Buccato S; Giovani C; Kratzer R; Zurli V; Mangiavacchi S; Casini D; Brito LM; De Gregorio E; Mason PW; Ulmer JB; Geall AJ; Bertholet S
J Virol; 2016 Jan; 90(1):332-44. PubMed ID: 26468547
[TBL] [Abstract][Full Text] [Related]
3. Vaccination with viral vectors expressing NP, M1 and chimeric hemagglutinin induces broad protection against influenza virus challenge in mice.
Asthagiri Arunkumar G; McMahon M; Pavot V; Aramouni M; Ioannou A; Lambe T; Gilbert S; Krammer F
Vaccine; 2019 Sep; 37(37):5567-5577. PubMed ID: 31399277
[TBL] [Abstract][Full Text] [Related]
4. Broadly neutralizing antibodies target a haemagglutinin anchor epitope.
Guthmiller JJ; Han J; Utset HA; Li L; Lan LY; Henry C; Stamper CT; McMahon M; O'Dell G; Fernández-Quintero ML; Freyn AW; Amanat F; Stovicek O; Gentles L; Richey ST; de la Peña AT; Rosado V; Dugan HL; Zheng NY; Tepora ME; Bitar DJ; Changrob S; Strohmeier S; Huang M; García-Sastre A; Liedl KR; Bloom JD; Nachbagauer R; Palese P; Krammer F; Coughlan L; Ward AB; Wilson PC
Nature; 2022 Feb; 602(7896):314-320. PubMed ID: 34942633
[TBL] [Abstract][Full Text] [Related]
5. A chimeric haemagglutinin-based universal influenza virus vaccine boosts human cellular immune responses directed towards the conserved haemagglutinin stalk domain and the viral nucleoprotein.
Bliss CM; Nachbagauer R; Mariottini C; Cuevas F; Feser J; Naficy A; Bernstein DI; Guptill J; Walter EB; Berlanda-Scorza F; Innis BL; García-Sastre A; Palese P; Krammer F; Coughlan L
EBioMedicine; 2024 Jun; 104():105153. PubMed ID: 38805853
[TBL] [Abstract][Full Text] [Related]
6. Imprinting and Editing of the Human CD4 T Cell Response to Influenza Virus.
Nelson SA; Sant AJ
Front Immunol; 2019; 10():932. PubMed ID: 31134060
[TBL] [Abstract][Full Text] [Related]
7. Antibodies elicited in humans upon chimeric hemagglutinin-based influenza virus vaccination confer FcγR-dependent protection in vivo.
Edgar JE; Trezise S; Anthony RM; Krammer F; Palese P; Ravetch JV; Bournazos S
Proc Natl Acad Sci U S A; 2023 Oct; 120(44):e2314905120. PubMed ID: 37871218
[TBL] [Abstract][Full Text] [Related]
8. Evidence That Blunted CD4 T-Cell Responses Underlie Deficient Protective Antibody Responses to Influenza Vaccines in Repeatedly Vaccinated Human Subjects.
Richards KA; Shannon I; Treanor JJ; Yang H; Nayak JL; Sant AJ
J Infect Dis; 2020 Jun; 222(2):273-277. PubMed ID: 31504634
[TBL] [Abstract][Full Text] [Related]
9. Influenza chimeric hemagglutinin structures in complex with broadly protective antibodies to the stem and trimer interface.
Zhu X; Han J; Sun W; Puente-Massaguer E; Yu W; Palese P; Krammer F; Ward AB; Wilson IA
Proc Natl Acad Sci U S A; 2022 May; 119(21):e2200821119. PubMed ID: 35594401
[TBL] [Abstract][Full Text] [Related]
10. Distinct and complementary roles of CD4 T cells in protective immunity to influenza virus.
Sant AJ; Richards KA; Nayak J
Curr Opin Immunol; 2018 Aug; 53():13-21. PubMed ID: 29621639
[TBL] [Abstract][Full Text] [Related]
11. Eliciting a single amino acid change by vaccination generates antibody protection against group 1 and group 2 influenza A viruses.
Ray R; Nait Mohamed FA; Maurer DP; Huang J; Alpay BA; Ronsard L; Xie Z; Han J; Fernandez-Quintero M; Phan QA; Ursin RL; Vu M; Kirsch KH; Prum T; Rosado VC; Bracamonte-Moreno T; Okonkwo V; Bals J; McCarthy C; Nair U; Kanekiyo M; Ward AB; Schmidt AG; Batista FD; Lingwood D
Immunity; 2024 May; 57(5):1141-1159.e11. PubMed ID: 38670113
[TBL] [Abstract][Full Text] [Related]
12. Multivalent next generation influenza virus vaccines protect against seasonal and pre-pandemic viruses.
Uno N; Ross TM
Sci Rep; 2024 Jan; 14(1):1440. PubMed ID: 38228649
[TBL] [Abstract][Full Text] [Related]
13. Chimeric hemagglutinin split vaccines elicit broadly cross-reactive antibodies and protection against group 2 influenza viruses in mice.
Puente-Massaguer E; Vasilev K; Beyer A; Loganathan M; Francis B; Scherm MJ; Arunkumar GA; González-Domínguez I; Zhu X; Wilson IA; Coughlan L; Sun W; Palese P; Krammer F
Sci Adv; 2023 Sep; 9(37):eadi4753. PubMed ID: 37703367
[TBL] [Abstract][Full Text] [Related]
14. Avian and Human Seasonal Influenza Hemagglutinin Proteins Elicit CD4 T Cell Responses That Are Comparable in Epitope Abundance and Diversity.
DiPiazza A; Richards K; Poulton N; Sant AJ
Clin Vaccine Immunol; 2017 Mar; 24(3):. PubMed ID: 28100497
[TBL] [Abstract][Full Text] [Related]
15. Enhanced CD103 Expression and Reduced Frequencies of Virus-Specific CD8
Surman SL; Jones BG; Woodland DL; Hurwitz JL
Viral Immunol; 2017 Dec; 30(10):737-743. PubMed ID: 29130830
[TBL] [Abstract][Full Text] [Related]
16. Universally Immune: How Infection Permissive Next Generation Influenza Vaccines May Affect Population Immunity and Viral Spread.
Bull MB; Cohen CA; Leung NHL; Valkenburg SA
Viruses; 2021 Sep; 13(9):. PubMed ID: 34578360
[TBL] [Abstract][Full Text] [Related]
17. Epistasis reduces fitness costs of influenza A virus escape from stem-binding antibodies.
Lee CY; Raghunathan V; Caceres CJ; Geiger G; Seibert B; Cargnin Faccin F; Gay LC; Ferreri LM; Kaul D; Wrammert J; Tan GS; Perez DR; Lowen AC
Proc Natl Acad Sci U S A; 2023 Apr; 120(17):e2208718120. PubMed ID: 37068231
[TBL] [Abstract][Full Text] [Related]
18. Use of Hemagglutinin Stem Probes Demonstrate Prevalence of Broadly Reactive Group 1 Influenza Antibodies in Human Sera.
Yassine HM; McTamney PM; Boyington JC; Ruckwardt TJ; Crank MC; Smatti MK; Ledgerwood JE; Graham BS
Sci Rep; 2018 Jun; 8(1):8628. PubMed ID: 29872070
[TBL] [Abstract][Full Text] [Related]
19. R-DOTAP Cationic Lipid Nanoparticles Outperform Squalene-Based Adjuvant Systems in Elicitation of CD4 T Cells after Recombinant Influenza Hemagglutinin Vaccination.
Henson TR; Richards KA; Gandhapudi SK; Woodward JG; Sant AJ
Viruses; 2023 Feb; 15(2):. PubMed ID: 36851752
[TBL] [Abstract][Full Text] [Related]
20. A new class of antibodies that overcomes a steric barrier to cross-group neutralization of influenza viruses.
Simmons HC; Watanabe A; Oguin Iii TH; Van Itallie ES; Wiehe KJ; Sempowski GD; Kuraoka M; Kelsoe G; McCarthy KR
PLoS Biol; 2023 Dec; 21(12):e3002415. PubMed ID: 38127922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
